Eingabe löschen

Kopfbereich

Hauptnavigation

Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin lymphoma in Switzerland

Beschreibung

Febrile neutropenia (FN) can be a serious complication of chemotherapy (CHT), increasing mortality risk and healthcare costs. Incidence and inpatient hospital costs of FN in Switzerland are currently not reported. The study aims to: 1. Estimate the number of CHT induced FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in Switzerland.

Eckdaten

Projektleitung

Dr. Renato Mattli, Mark Pletscher

Projektteam

Prof. Dr. Klaus Eichler, Prof. Dr. Simon Wieser

Projektpartner

Amgen Switzerland AG

Projektstatus

abgeschlossen, 10/2012 - 12/2013

Institut/Zentrum

Winterthurer Institut für Gesundheitsökonomie (WIG)

Drittmittelgeber

Dritte